Vlot MC, et al. - During the first year of hormonal treatment (HT), researchers explored changes in bone turnover markers (BTMs), sclerostin, and correlations with BMD change in trans women and trans men. For this investigation, 121 trans women (median age 30 years) got estradiol and anti-androgens, and 132 trans men (median age 24 years) got testosterone. According to findings, lower bone turnover for trans women and older trans men resulted from 1-year of HT, while in younger trans men it increased. The importance of estrogen as the key regulator of bone turnover was shown in the reduction in bone resorption in older trans men. A decrease in all BTMs was found in trans men aged ≥ 50 years vs the other age groups; there were no age differences in trans women. There was a weak correlation between changes in BTMs and BMD.